Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01862835 · ClinicalTrials.gov registry record · Phase 1
Impact of Estradiol Addback
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01862835: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01862835 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01862835, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
Repletion of testosterone (T) in older men drives Growth Hormone secretion after its aromatization to estradiol (E2) by potentiating endogenous GH drive.
Interventions
- DRUG Anastrozole
- DRUG Degarelix
- DRUG Testosterone
- DRUG Estrogen patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-05 |
| Est. Completion | 2018-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01862835
The ClinicalTrials.gov registry entry for NCT01862835 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Anastrozole is the first listed.
NCT01862835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01862835 about?
NCT01862835 is a clinical study titled "Impact of Estradiol Addback". Repletion of testosterone (T) in older men drives Growth Hormone secretion after its aromatization to estradiol (E2) by potentiating endogenous GH drive.
What is the current status of trial NCT01862835?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2013-05. Estimated completion is 2018-12-30.
What interventions are being tested in trial NCT01862835?
The interventions under investigation include: Anastrozole (DRUG), Degarelix (DRUG), Testosterone (DRUG), Estrogen patch (DRUG).
Who is sponsoring clinical trial NCT01862835?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.